Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). This is an ASCO Meeting Abstract from the 2019 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results